BioCentury | Dec 3, 2020
Deals
Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality
Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...